A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma

Trial Profile

A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Dec 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Brentuximab vedotin
  • Indications Hodgkin's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms KEYNOTE-204
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 13 Feb 2017 Planned End Date changed from 1 Aug 2019 to 1 Dec 2019.
    • 13 Feb 2017 Planned primary completion date changed from 1 Feb 2018 to 1 May 2018.
    • 11 Oct 2016 Trial design presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top